Lenire ®.: Difference between revisions
mNo edit summary |
mNo edit summary |
||
| (5 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
Panakès Allies is | Panakès Allies is a Venture Capital company, based in Milan, which purchases the most ambitious business and groups, establishing cutting edge technologies and items, in the area of life scientific researches, intending to improve the lives of people all over the world.<br><br>Founded in 2010 by Dr. Ross 'Neill, [https://www.protopage.com/odwaceojwe Bookmarks] CEO, Neuromod Instruments is a medical modern technology business that specialises in the style and advancement of neuromodulation innovations to address the professional demands of underserved patient populations that live with persistent and debilitating conditions.<br><br>Because the previous round of funding elevated in October 2020, the company has made development commercialising Lenire, broadening the tool's availability throughout Europe, developing a wholly owned United States subsidiary, Neuromod United States Inc, and protecting US market authorization from the FDA. <br><br>The latest financing - which more than doubles the cash the NUI Maynooth spin-out has actually raised since it was founded in 2010 - is split equally in between endeavor debt financing from the European Financial investment Financial institution and new equity investment. | ||
Latest revision as of 18:50, 15 June 2024
Panakès Allies is a Venture Capital company, based in Milan, which purchases the most ambitious business and groups, establishing cutting edge technologies and items, in the area of life scientific researches, intending to improve the lives of people all over the world.
Founded in 2010 by Dr. Ross 'Neill, Bookmarks CEO, Neuromod Instruments is a medical modern technology business that specialises in the style and advancement of neuromodulation innovations to address the professional demands of underserved patient populations that live with persistent and debilitating conditions.
Because the previous round of funding elevated in October 2020, the company has made development commercialising Lenire, broadening the tool's availability throughout Europe, developing a wholly owned United States subsidiary, Neuromod United States Inc, and protecting US market authorization from the FDA.
The latest financing - which more than doubles the cash the NUI Maynooth spin-out has actually raised since it was founded in 2010 - is split equally in between endeavor debt financing from the European Financial investment Financial institution and new equity investment.